Skip to content
Open access

Gut Commensal Bacteria Ameliorate Liver Fibrosis by Inhibiting Macrophage M1 Polarization Through Secondary Bile Acids in a Murine Liver Fibrosis Model

Sep 2026 · Microorganisms · Vol 14, pp. 2035 · 0 citations · 59 references
Medicine

TL;DR

The results demonstrate that the gut microbiota–secondary bile acid–TGR5 signaling axis plays a critical role in liver fibrosis and represents a promising therapeutic target.

Abstract

The gut microbiota plays a critical role in regulating liver metabolism and immunity, significantly influencing hepatic inflammation and fibrogenesis. However, the mechanisms by which it modulates the progression of liver fibrosis remain unclear. This study investigated the interplay between the gut microbiota and bile acids in murine liver fibrosis. A mouse model of liver fibrosis was established via intraperitoneal injection of carbon tetrachloride. The gut microbiota was depleted using an antibiotic cocktail, as confirmed through 16S rRNA sequencing. Bile acid profiles were measured using ultra-performance liquid chromatography–tandem mass spectrometry. The effects of secondary bile acids on macrophage polarization were assessed in vivo and in vitro. Gut commensal microbiota depletion exacerbated liver inflammation and fibrosis. Concomitantly, this depletion significantly reduced microbiota-derived secondary bile acids. Notably, supplementation with deoxycholic acid markedly attenuated liver fibrosis. This protective effect was associated with the inhibition of pro-inflammatory M1 macrophage polarization. Takeda G protein-coupled receptor 5 (TGR5) activation was identified as the mechanism underlying the effect of deoxycholic acid on macrophages, as a TGR5 antagonist reversed this inhibition. Mechanistically, TGR5 activation suppressed the NF-κB pathway in macrophages via the cAMP–PKA signaling cascade, thereby inhibiting hepatic stellate cell activation. Our results demonstrate that the gut microbiota–secondary bile acid–TGR5 signaling axis plays a critical role in liver fibrosis and represents a promising therapeutic target.

Read PDF

Similar papers

Open access Oct 2026

Butyrate ameliorates acute‐on‐chronic liver failure by regulating macrophage polarization

Gut microbiota dysbiosis and its metabolite disorders may drive the progression of hepatitis B virus‐related acute‐on‐chronic liver failure (HBV‐ACLF) through the gut–liver axis, but the specific mechanisms and intervention targets remain unclear. Blood and stool samples were collected from 50 patients with liver dis...

Jing Xiao, Hang You, Zong-Yi Liu et al. · 0 citations
Open access Sep 2026

MiR-29a deficiency disrupts gut microbiota-bile acid homeostasis and impairs the anti-inflammatory effects of lithocholic acid in colitis

Background Gut microbiota, bile acid metabolism, and their derived metabolites are critical regulators of intestinal inflammation in inflammatory bowel disease (IBD). While microRNA-29a (miR-29a) is a recognized epigenetic regulator of intestinal inflammation, its role in shaping microbiota-driven bile acid metabolism,...

Xi Xiao, Qian Gong, Xue-Jian Zheng et al. · 0 citations
Open access Oct 2026

Lactobacillus reuteri attenuates chronic diarrhea by modulating microbiota homeostasis and macrophage polarization through the cGAS/STING pathway dependent on D-lactate-mediated mitochondrial function.

Chronic diarrhea (CD) severely affects patients' quality of life and is linked to ulcerative colitis, inflammatory bowel disease, and colorectal cancer. Gut microbiota dysbiosis plays a crucial role in intestinal health, with Lactobacillus reuteri emerging as a key regulator. However, its role in chronic diarrhea remai...

Xu-Kai Cheng, Yi-Ning Zhang, Chao Li et al. · 0 citations
Sep 2026

Gut Microbiota-Derived Indole-3-propionic Acid Attenuates Titanium Dioxide Nanoparticle-Induced Liver Injury by Targeting Kupffer Cells via the Gut-Liver Axis.

Nanotitanium dioxide (nTiO2) is widely used as a food additive, leading to chronic dietary exposure and rising health concerns. Although adverse effects on the liver and gut microbiota have been individually investigated, whether gut microbiota mediates nTiO2-induced liver injury remains unclear, especially given the w...

Jie Li, Jiao Li, Yu-Li Chen et al. · 0 citations
Review Open access Oct 2026

Gut microbiota in hepatocellular carcinoma: pathogenic mechanisms and clinical translation

The gut microbiota is an important modulator of host metabolism and immunity. In hepatocellular carcinoma (HCC), the most common form of primary liver cancer, dysbiosis, impaired intestinal barrier integrity, and dysregulated host-microbial immune signaling are considered contributing factors to disease progression. Th...

Ke-Han Zhang, Tian-Chen Xue, Jie Hu et al. · 0 citations
Open access Nov 2026

Cholic acid supplementation alleviated gut-liver injury and remodeled the gut microbiota in Escherichia coli-infected mice.

BACKGROUND Pathogen infection contributes to diarrhea, intestinal inflammation, and even death of animals. Thus, finding efficient drugs for alleviating or preventing bacterial infection is quite urgent for animal production. Bile acids have been recognized as important signaling molecules to regulate gut-liver homeost...

Shu-Qian Zhang, Ya-Shi Hu, Lu-Yao Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.